Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...
The Physicians Really Are Healing Themselves, With Ozempic
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
Super Bowl ad sparks controversy over cut-rate Wegovy alternative
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
BioSpace3d
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Lilly's profit forecast bring investors some relief amid Zepbound miss
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...
FiercePharma4d
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...